In a recent case, Roche Molecular Systems, Inc. v. Cepheid, the Federal Circuit affirmed that claims directed to a nucleotide primer and claims directed to a detection method are invalid under 35 USC § 101. The patent covered primers and methods for a rapid detection of M. tuberculosis on the basis of the presence of […]